ArticleJournal of virology2004
Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- N-arylpyrimidinamine (NAPA) compounds are broadly acting inhibitors of human cytomegalovirus infection and spread.Antiviral research · 2025Article
- Targeted mutagenesis of the herpesvirus fusogen central helix captures transition states.Nature communications · 2023Article
- Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirus.Antiviral research · 2023Article
- Review
- Peptide Derivatives of Platelet-Derived Growth Factor Receptor Alpha Inhibit Cell-Associated Spread of Human Cytomegalovirus.Viruses · 2021Article
- Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion.Science advances · 2021Article
- Chiral Thioureas-Preparation and Significance in Asymmetric Synthesis and Medicinal Chemistry.Molecules (Basel, Switzerland) · 2020Review
- Restriction of Human Cytomegalovirus Infection by Galectin-9.Journal of virology · 2019Article
- Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.ACS medicinal chemistry letters · 2016Article
- Current and potential treatments for ubiquitous but neglected herpesvirus infections.Chemical reviews · 2014Review
- Interplay between human cytomegalovirus and intrinsic/innate host responses: a complex bidirectional relationship.Mediators of inflammation · 2012Review
- Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.Pharmacology & therapeutics · 2011Review
- The search for new therapies for human cytomegalovirus infections.Virus research · 2011Review
- Synthesis and SAR studies on azetidine-containing dipeptides as HCMV inhibitors.Bioorganic & medicinal chemistry · 2011Article
- Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus.Antimicrobial agents and chemotherapy · 2010Article
- Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.Antimicrobial agents and chemotherapy · 2008Article
- Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells.Journal of virology · 2007Article
- Postattachment events associated with viral entry are necessary for induction of interferon-stimulated genes by human cytomegalovirus.Journal of virology · 2004Article
- An acidic cluster of human cytomegalovirus UL99 tegument protein is required for trafficking and function.Journal of virology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel small molecule inhibitor of human cytomegalovirus (HCMV) was identified as the result of screening a chemical library by using a whole-virus infected-cell assay. Synthetic chemistry efforts yielded the analog designated CFI02, a compound whose potency had been increased about 100-fold over an initial inhibitor. The inhibitory concentration of CFI02 in various assays is in the low nanomolar range. CFI02 is a selective and potent inhibitor of HCMV; it has no activity against other CMVs, alphaherpesviruses, or unrelated viruses. Mechanism-of-action studies indicate that CFI02 acts very early in the replication cycle, inhibiting virion envelope fusion with the cell plasma membrane. Mutants resistant to CFI02 have mutations in the abundant virion envelope glycoprotein B that are sufficient to confer resistance. Taken together, the data suggest that CFI02 inhibits glycoprotein B-mediated HCMV virion fusion. Furthermore, CFI02 inhibits the cell-cell spread of HCMV. This is the first study of a potent and selective small molecule inhibitor of CMV fusion and cell-cell spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.